Core Insights - NKGen Biotech has appointed Dr. Anita Fletcher as the National Principal Investigator for its Phase 2a clinical trial of troculeucel, an enhanced autologous NK cell therapy for moderate Alzheimer's disease [1][2] - The trial aims to enroll patients with moderate stage Alzheimer's disease, where currently 30% of patients lack approved disease-modifying therapies [2] - The first clinical site for the trial will be AdventHealth Research Institute in Orlando, Florida [1] Company Overview - NKGen Biotech is a clinical-stage biotechnology company focused on developing innovative autologous and allogeneic NK cell therapeutics [12] - Troculeucel, the company's drug candidate, is a patient-specific, ex vivo expanded autologous NK cell immunotherapeutic aimed at treating neurodegenerative disorders and various cancers [5] - The International Nonproprietary Name (INN) for troculeucel has been assigned as SNK01 by the World Health Organization, marking a significant milestone for the company [5] Clinical Trial Details - The Phase 2a trial will utilize a cryopreserved product delivered at a high dose of 6 x 10^6 cells every three weeks for one year [4] - Previous Phase 1 trial results indicated that 90% of evaluable subjects had stable or improved composite ADCOMS scores at Week 11, with no treatment-related adverse events reported [8] Research and Community Impact - AdventHealth, the clinical site partner, has a robust research portfolio with over 675 clinical trials and studies in progress, demonstrating a strong commitment to community health [9] - The organization invested over $1.26 billion in community services in 2023, highlighting its dedication to improving healthcare access and quality [9]
NKGen Appoints Dr. Anita Fletcher as National Principal Investigator for Phase 2a Troculeucel Trial Evaluating Moderate Alzheimer’s Disease with AdventHealth Orlando as First East Coast Site